INKT DCF Valuation - Mink Therapeutics Inc

Watchlist Manager

Watchlist

Price: 11.02 USD 14.43% Market Closed

Market Cap: $51.7m

	Mink Therapeutics Inc NASDAQ:INKT	US
	Novogene Co Ltd SSE:688315	CN
	Global Energy Ventures Ltd ASX:GEV	AU
	Castle Minerals Ltd ASX:CDT	AU
	Qube Holdings Ltd ASX:QUB	AU
M	Murray Cod Australia Ltd ASX:MCA	AU
T	Tiger Brands Ltd JSE:TBS	ZA
	Scidev Ltd ASX:SDV	AU
G	Galaxia SM Inc KRX:011420	KR
	Watkin Jones PLC LSE:WJG	UK
B	Boilermech Holdings Bhd KLSE:BOILERM	MY
S	SIK Cheong Bhd KLSE:SCB	MY
S	Shopify Inc LSE:0VHA	CA
H	Human Creation Holdings Inc TSE:7361	JP
	nLIGHT Inc NASDAQ:LASR	US
H	Haypp Group AB (publ) STO:HAYPP	SE
	Hempacco Co Inc OTC:HPCO	US
	Bank of The Ryukyus Ltd TSE:8399	JP
	Blue Prism Group PLC LSE:PRSM	UK
P	Platina Resources Ltd ASX:PGM	AU
	Caesarstone Ltd NASDAQ:CSTE	IL
	Fagerhult AB STO:FAG	SE
	Jones Lang LaSalle Inc NYSE:JLL	US
	Fine-Line Circuits Ltd BSE:517264	IN

INKT's DCF value cannot be reliably calculated.

Relative Valuation Wall Street Price Targets

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.